Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and quality of life for combining Abemaciclib with either an Aromatase Inhibitor or Fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase IV trial focuses on both pre- and postmenopausal patients receiving first-line treatment. A digital health app called CANKADO will be used to track side effects and patient-reported outcomes daily, alongside standard documentation. The study also aims to explore biomarkers to better understand treatment responses and resistance. Participants will receive either Abemaciclib combined with an Aromatase Inhibitor Anastrozole, Letrozole, or Exemestane taken orally twice daily plus daily Aromatase Inhibitor tablets every 24 hours in 28-day cycles, or Abemaciclib with Fulvestrant which is given as an injection on specific days within 28-day cycles. The two treatment groups are experimental and non-randomized, with no masking. The trial includes monitoring for side effects and quality of life throughout treatment. During the study, participants will regularly report side effects and global health status using questionnaires at multiple time points up to 24 months, including specialized breast cancer quality of life modules. Researchers will assess progression-free survival up to 48 months, as well as adverse events, hospitalizations, clinical benefit rate, overall survival, and tumor response. The use of the CANKADO app for side effect reporting is strongly recommended but not mandatory. Participants will be followed for safety and outcomes throughout the trial duration.
Actively Recruiting
Researchers are investigating treatment options for Waldenstrf6ms macroglobulinemia WM, a condition where chemotherapy often results in low complete or very good partial response rates and limited duration of response. WM patients tend to be older and may not tolerate chemotherapy side effects well, so treatments without chemotherapy are especially appealing. Venetoclax, a drug approved for related blood cancers, has shown promising activity and low toxicity in WM patients, including those previously treated with Ibrutinib or with certain genetic mutations. Ibrutinib, while effective, requires continuous use and its success varies with genetic factors, limiting its adoption as a standard treatment. Fixed-duration treatment combining Venetoclax and Rituximab has shown deep responses in related diseases, suggesting it might improve outcomes for newly diagnosed WM patients. The study is an international, phase II, open-label, randomized trial comparing two treatment approaches for newly diagnosed WM patients needing therapy. One group receives a combination of Venetoclax and Rituximab, with Venetoclax dose gradually increased during the first 28-day cycle and continued for 12 cycles alongside Rituximab given intravenously monthly. The other group receives a combination of Dexamethasone, Rituximab, and Cyclophosphamide for six 28-day cycles. The study uses genetic markers MYD88 and CXCR4 to stratify patients before randomization. About 80 patients will participate across multiple sites. Participants will be monitored for treatment response and safety during and after therapy, with assessments including response rates at 12 and 24 months, progression-free survival over six years, and quality of life measured by questionnaires. Safety evaluations involve tracking adverse events, laboratory tests, heart monitoring, and vital signs over 12 months. The main goal is to see if Venetoclax plus Rituximab leads to better deep response rates compared to the standard chemotherapy combination. This trial aims to provide data supporting new treatment standards for WM.
Actively Recruiting
This research aims to gather a large group of patients diagnosed with BCR-ABL 1-negative myeloid neoplasms, classified according to WHO 20082016 standards. The study focuses on collecting detailed clinical, biological, and quality-of-life data to better understand disease characteristics, outcomes, and potential prognostic markers. It is an observational registry conducted by the University of Ulm to improve knowledge about this condition over time. Participants in this registry will provide various biological samples, such as bone marrow aspirate, peripheral blood, plasma, buccal swabs, and occasionally skin biopsies. These samples will be used for morphological and genetic analysis. The study does not involve any experimental treatments but collects comprehensive data and samples to assess disease features and clinical outcomes. Throughout the study, researchers will collect clinical information using a defined catalog of relevant variables and assess quality of life with specific symptom assessment forms. They will track outcomes including treatment decisions, responses, overall survival, progression-free survival, and duration of response for up to 25 years. This long-term follow-up allows detailed monitoring of patient health and disease progression.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two treatment strategies for patients newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer. This international, multicenter, randomized, open Phase III trial compares carboplatinpaclitaxel chemotherapy followed by niraparib alone versus carboplatinpaclitaxel combined with bevacizumab followed by both bevacizumab and niraparib. The study includes patients with high-grade, non-mucinous, non-clear cell epithelial tumors at specific advanced stages who have had surgery or plan chemotherapy with interval debulking surgery. All patients receive an initial cycle of carboplatin and paclitaxel before randomization. After central testing of tumor BRCA status, participants are randomly assigned to one of two arms Arm 1 continues with five more cycles of carboplatin and paclitaxel followed by daily niraparib for up to three years Arm 2 receives five cycles of carboplatin and paclitaxel plus bevacizumab, then maintenance bevacizumab for up to one year alongside daily niraparib for up to three years. This design aims to determine if adding bevacizumab improves outcomes over the standard treatment. Participants undergo frequent assessments including scans and laboratory tests to monitor progression-free survival and other health outcomes. Researchers also evaluate overall survival, time to additional therapies, treatment-related side effects, and quality of life up to several years after enrollment. Patients attend regular visits for treatment, monitoring, and completion of questionnaires, with safety follow-up 30 days after the last dose. The entire observation period can last up to 66 months after the last patient joins the trial.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.
Actively Recruiting
Researchers are observing patients with documented HER2-positive, HER2-low, or HER2-ultralow unresectable or metastatic breast cancer who are receiving trastuzumab deruxtecan T-DXd treatment. The study evaluates patient-reported outcomes as well as real-world effectiveness and safety of T-DXd when used according to the approved product guidelines within routine clinical practice in Germany. Additionally, patients will be informed about using a digital healthcare application DiGA. Participants receive T-DXd treatment as part of their routine care, with no specific treatment schedule dictated by the study protocol. The study includes two groups one with HER2-positive breast cancer patients and another with HER2-low or HER2-ultralow patients, each group expected to enroll approximately 400 participants. All diagnostic and treatment decisions, including visit frequency, are managed by the treating physician. During the study, participants health and treatment progress will be tracked, including patient-reported quality of life assessments using FACT-B and FACT-G questionnaires at six months. Researchers will monitor the time from first T-DXd dose to the next treatment or death, assessed for up to 60 months. The study lasts until December 2031, with ongoing observation of real-world treatment outcomes and safety.
Actively Recruiting
The trial investigates adjuvant treatment options for women with endometrial cancer characterized by mismatch repair deficiency MMRd. It is a phase III international, multicenter, randomized study comparing pelvic external beam radiotherapy combined with and followed by durvalumab for one year to pelvic external beam radiotherapy with or without chemotherapy. This trial is part of the larger RAINBO research project which aims to refine adjuvant treatment based on molecular features of endometrial cancer. Participants receive either pelvic external beam radiotherapy alone or combined with chemotherapy according to the PORTEC-3 schedule, or pelvic external beam radiotherapy plus durvalumab given intravenously every 4 weeks for 13 cycles one year. Vaginal brachytherapy may be considered for certain patients with specific tumor involvement. The trial includes detailed radiation dosing and chemotherapy regimens, with durvalumab starting within the first week of radiotherapy. Participants will be monitored for recurrence-free survival over three years, along with efficacy, quality of life, safety, and biomarker outcomes for up to five years. Assessments include clinical evaluations, imaging, laboratory tests, and translational research on tumor material. The study requires follow-up and treatment accessibility, with informed consent and permissions for research use of tissue and data. The total duration includes treatment and long-term follow-up to evaluate treatment impact and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of relacorilant combined with other treatments in patients with gynecological cancers in this Phase 2, open-label, global, multi-arm study. The study aims to test different treatment combinations in separate groups, including patients with ovarian and endometrial cancers, to assess how these combinations may affect disease progression and patient health. Participants in Arms A and B will receive relacorilant combined with nab-paclitaxel and bevacizumab. Relacorilant is given orally once daily under fed conditions for three days around the time of nab-paclitaxel infusion, which is administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is given intravenously on Days 1 and 15 in Arms A and B. Arm C participants receive relacorilant with nab-paclitaxel but without bevacizumab. Treatment continues until disease progression, unacceptable side effects, or other criteria lead to discontinuation. During the study, participants will have their cancer progression monitored through measures like progression-free survival up to 18 months. Researchers will also assess response rates, duration of response, clinical benefit, overall survival, and collect drug concentration data at specified cycle days. Safety will be monitored through adverse event reporting from the first dose until 30 days after treatment ends. The study is expected to be completed by December 2026.
1-10 of 13
1